Q-omics provides the consensus-scored MYL12B profile across patient tissues and cancer cell-line models. MYL12B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MYL12B is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MYL12B RNA expression shows 18,788 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KICH, and ACC as cancer lineages where MYL12B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYL12B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYL12B survival associations across molecular data types. MYL12B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYL12B RNA expression–survival associations across cancer types. High MYL12B expression shows unfavorable associations in HNSC, ACC, UVM and LGG, but favorable associations in THCA and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MYL12B RNA expression.
This table summarizes MYL12B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MYL12B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYL12B shows lower tumor expression in KICH and LUAD and higher tumor expression in BLCA, LIHC, HNSC and THCA. The KICH box plot shows higher MYL12B RNA expression in normal versus tumor tissue (log2 FC = −1.401, t-test p < 0.001).
This table shows molecular features associated with MYL12B in patient tissues and cancer cell lines. In patient samples, MYL12B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYL12B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
